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INTRODUCTION 
Diabetes Mellitus is the most common endocrine disorder 
world over and India is considered the world capital of this disease. 
Among the different types of diabetes Type 2 DM is the most common 
type. It has a prevalence of nearly 5.5% worldwide and according to 
WHO statistics there are nearly 147 million people worldwide with 
Diabetes at present. By 2030 Diabetes would be the 7
th
 leading cause of 
death and 80% of these deaths would occur in developing and under 
developed countries.  
Type 2 DM affects nearly every physiological process in the 
body hence its wide ranging systemic effects. 
Diabetes, of any variety, is characterized by hyperglycemia, a 
lack of insulin (absolute or relative), and the development of diabetes-
specific micro vascular pathology such as retinopathy, nephropathy and 
neuropathy. Accelerated atherosclerotic macro vascular disease that   
affect the blood vessels which supply the heart, brain, and lower 
extremities is also associated with diabetes. 
Diabetic Retinopathy is an important micro vascular 
complication and is the most common cause of blindness in the 
developed world. The disease is characterized by progressive changes in 
retinal microvasculature leading to retinal hypo perfusion, increased 
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vascular permeability and neovascularization causing severe and 
permanent blindness. 
Thyroid disorders are another common endocrine problems 
second only to diabetes. Most of the cells in our body need the thyroid 
hormone for functioning properly as it has effects on a significant number 
of physiological processes. Hence it is not unusual for an patient to be 
affected by both Type 2 DM and thyroid disorders. There are varying 
reports regarding the prevalence of thyroid dysfunction among diabetics, 
most common thyroid abnormality being sub clinical hypothyroidism. 
The two conditions have strong association and have important 
clinical implications for treatment and insulin sensitivity. 
Impaired renal clearance is said to be an important cause of the 
reduction in insulin requirements in hypothyroidism. Decreased 
gluconeogenesis makes these patients highly prone for hypoglycemia. 
Diabetic patients have a increased frequency of retinopathy 
 
and 
nephropathy when associated with subclinical hypothyroidism. At the 
same time the severity of retinopathy in these patients is said to be more. 
Even subclinical hypothyroidism has a negative impact on lipid 
metabolism and it is an independent risk factor for myocardial infarction 
and retinopathy. 
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Another possible mechanism linking Subclinical 
hypothyroidism to vascular diseases is the finding that thyroid hormones 
inhibit collagen induced platelet aggregation and directly relax smooth 
muscles. 
Further hypothyroidism is accompanied by a hypercoagulable 
state and increased blood viscosity.
 
 
Hyperthyroidism is seen less commonly in Diabetes, but is 
associated with higher risk of development of potentially life-threatening 
ketoacidosis. Therefore, detection and correction of thyroid abnormalities 
is essential for proper diabetic control as well as for prevention of 
diabetic complications as it may greatly increase the quality of life in 
these patients. 
 
At the molecular level, thyroid hormone has cell surface 
receptors for integrin ανβ3 that mediates the angiogenetic activity of 
thyroid hormones and integrin ανβ3 has pro - angiogenic effects on 
growth factors implicated in the pathogenesis of retinal new vessels, 
including erythropoietin, growth hormone, basic fibroblast growth factor 
(bFGF), insulin-like growth factor 1 (IGF-1), and VEGF. 
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Thyroid hormone has well documented effects on new vessel 
formation. These effects are mediated via integrin receptor for the thyroid 
hormones on the vascular smooth muscle cells and endothelial cells and 
reflect the relation between genomic and nongenomic mechanisms 
invoked by the thyroid hormones. 
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REVIEW OF LITERATURE  
 
DIABETES MELLITUS AND THYROID 
The term ‗diabetes‘ has been  derived from Greek word ‗dia‘ 
(through) and ‗bianeon‘ (to go), meaning a siphon, ―because fluid does 
not remain in body but uses man‘s body as a ladder whereby to leave it as 
if patient was a siphon‖ which described polyuria, by the legendry Greek 
physician Aretaeus . He described the disease as ―… melting down of 
flesh into urine, thirst unquenchable, kidneys never stop making water‖
 
During 5
th 
and 6
th 
century BC, sweet taste of urine in polyuric 
patients was also described in Sanskrit (Indian) literature by Susruta, 
Charaka and Vaghbata and the disease was named ―Madhumeha‖. They 
described that the urine of these patients tasted like honey (madhu), 
sticky to touch and ants were strongly attracted to it. They differentiated 
two forms of the disease, one affecting thin people who do not survive 
long and the other, affecting older and obese. They also described relation 
of diabetes to hereditary, obesity, sedentary life and diet. This description 
was parallel to the subdivision of diabetes into type 1 and 2 diabetes.  
Indian literature gets credit for the term ―honey urine‖ referring 
to the clear colourless nature of diabetic urine. 
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      THE THYROID GLAND 
The thyroid gland was known at least from the time of Galen, 
who thought it provided a fluid for the lubrication of the larynx.  
Andrecos Vesslius (1514-64) gave the first description of the 
thyroid gland as two glands on each side of the root of the larynx which 
are large fungus like, flesh colored and covered with blood vessels.  
Eustachius (1520-74 Ad) discovered the isthmus of the thyroid 
gland. The anatomical site, size and weight were described by Wharton 
(1614-73 AD) in his book Adenographia. 
Scharge noted special blood supply of the thyroid. It was 
alberchut Von hallen (1768 - 78) who classified thyroid among the 
ductless gland.  
The Thyroid hormone, thyroxine was first isolated by Dendall 
of Mayo clinic in 1915. CR. Harrington (1925) determined the chemical 
constitution and devised means for artificial synthesis and pointed out the 
principal chemical features responsible for specific physiological activity 
(F Cuelly 1961).  
Endemic goitre was known to doctors of antiquity in India, 
china and Greece.  
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    CRITERIA OF AMERICAN DIABETIC 
ASSOCIATION FOR      DIABETES MELLITUS   DIAGNOSIS 
1. A1C > 6.5%. This test must be performed in a lab using a 
technique that is   certified by the NGSP and standardized to the Diabetic 
control and complication trial(DCCT)assay.*  
OR 
2. FPG > 126 mg/dl (7.0mmol/l). Fasting is defined as plasma 
glucose after 8 hours   fasting (no calorie intake). 
OR 
3. 2-h plasma glucose load of ≥ 200 mg/ dl (11.1 mmol/ l) 
during an OGTT. The test should be done as described by the WHO, after 
giving a glucose load that is the equivalent of 75 g anhydrous glucose 
dissolved in water.*  
OR 
4. In a patient with symptoms of hyperglycaemic crisis or       
hyperglycaemia, a random glucose of ≥ 200 mg/dl(11.1 mmol/l) 
 
*In the absence of unequivocal hyperglycemias, criteria 1-3    
should be     confined by repeat testing. 
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DIABETES MELLITUS – CHRONIC COMPLICATIONS 
Microvascular complications 
Eye disease 
Nephropathy  
Retinopathy (nonproliferative/proliferative)  
Macular edema  
Neuropathy (Motor , sensory and autonomic)  
(mono - and polyneuropathy) 
Macrovascular complications 
Cerebrovascular disease 
Coronary artery disease  
Peripheral vascular disease  
Others 
Genitourinary (sexual/ uropathy dysfunction)  
Dermatologic 
Gastrointestinal (gastroparesis, diarrhea)  
Increased risk of infections 
Cataracts  
Glaucoma  
Dental abnormalities    
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      RETINAL ANATOMY AND PHYSIOLOGY 
The retina (―network‖) consists of five fundamental types of 
cellular elements: neurons, glial cells, microglia, blood vessels, and 
pigment epithelium.  Intact connections and communications between 
these cells are required for normal vision. 
Neurons- The neurons and glial cells of the retina comprise 
more than 95% of the retinal mass, but they are transparent to visible 
light, so their structure and function are not readily apparent on clinical 
examination. 
Primarily the retina is a neural tissue, and retinal neurons, the 
cells that define vision, include photoreceptors, amacrine, bipolar, 
horizontal, and ganglion cells. Electrical inputs from the first four types 
of neurons converge on the ganglia, and the ganglion cells‘ electrical 
output is conducted to the brain via axons of the nerve fiber layer and 
optic nerve. The high degree of convergence and integration of retinal 
signals is evident in the 10:1 ratio of photoreceptors (≈130 million) to 
ganglion cells (≈1.2 million) per human eye. Therefore, disruption of any 
of the neuronal layers interferes with vision, but redundancy of the 
neuronal architecture allows for many cells to die or malfunction before 
visual function is impaired. For example, at least 50% of ganglion cells in 
an area are lost before a clinically detectable visual defect is apparent in 
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patients with glaucoma, and an eye can retain 20/20 acuity with less than 
10% of cone photoreceptors. 
 Glial Cells- The glial (―glue‖) cells of the retina— astrocytes 
and Muller cells —act as supporting cells for the blood vessels and 
neurons. They regulate extracellular ion concentrations necessary for 
generating action potentials, metabolize neurotransmitters such as 
glutamate, and transport substrates for retinal metabolism (glucose, lipids, 
and amino acids) from blood vessels to neurons. Their role in glutamate 
handling is particularly important because excess glutamate in response 
to retinal ischemia or diabetes is toxic to neurons and may contribute to 
neuronal cell death. 
In addition to their effects on neurons, astrocytes guide fetal 
vascular development from the optic nerve to the peripheral retina and 
influence the function and integrity of mature vessels. Major cytokine 
involved in this process is vascular endothelial growth factor and is 
produced by astrocytes and Muller cells. Astrocytes also signal blood 
vessels to acquire barrier properties to form the blood–retina barrier and 
influence the development of tight junctions in retinal endothelial cells , 
and regulate the function of retinal synapses and, therefore, visual 
function. However, many details of the means by which glial cells control 
normal retinal function remain uncertain. 
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Microglial Cells- Microglia are bone marrow-derived 
macrophages that reside in the retina and sense the retinal metabolic 
environment. They respond to a variety of stimuli, such as retinal 
detachment, infection or trauma (including laser photocoagulation) by 
proliferating, migrating, and releasing inflammatory cytokines, such as 
interleukin-1, VEGF, and tumor necrosis factor-α. Retinal injury 
increases the migration of bone marrow-derived immune cells into the 
retina and their differentiation into microglia cells. In the short term, 
these responses may represent a beneficial response to the injury, but 
prolonged activation results in chronic inflammation and cellular damage. 
Blood Vessels- The retinal vascular circuit consists of conduits 
into and out of the retina. Precapillary arterioles, capillaries, and 
postcapillary venules are included in microcirculation. Smooth muscle 
cells in arterioles allow the arterioles to change their radius and 
dynamically regulate local delivery of blood to the retina. Precapillary 
arterioles are the primary resistance vessels, whereas venules have a high 
density of receptors for vasoactive agents, such as histamine. Passive 
conducting tubes are primarily the venules, which drain blood out of the 
retina. Capillaries and venules are the primary sites of fluid diffusion into 
the retina under normal conditions, and this diffusion increases in 
pathologic conditions such as diabetes. 
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Blood vessels of the central nervous system have a general 
feature of autoregulation by which the organ maintains appropriate blood 
flow despite changes in systemic arterial pressure. Smooth muscle cells in 
retinal arterial vessesls, while pericytes in capillaries, arterioles, and 
venules, function as modified smooth muscle cells. These features allow 
the retinal circulation to autoregulate in response to local and systemic 
metabolic demands. Blood vessels also autoregulate in response to the 
partial pressure of the oxygen (pO2) and carbon dioxide (pCO2). 
Therefore, vessels constrict in response to hyperoxemia and dilate in 
response to hypercapnea. Under normal conditions, retinal blood flow 
balances nutrient delivery and waste removal with retinal metabolism. 
Diabetes, a systemic malfunction of carbohydrate,lipid, and protein 
metabolism, leads to vascular and tissue damage in organs such as the 
retina. Thus, diabetic retinopathy is fundamentally a disorder of retinal 
and systemic metabolism that damages the retinal tissue elements and 
associated vessels; that is, a neurovascular degeneration or sensory 
neuropathy. 
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Clinical Risk Factors for Diabetic 
Macular Edema and Retinopathy 
Poor metabolic control 
Hypertension (>130/80 mm Hg) 
Intravascular fluid overload 
Congestive heart failure 
Renal failure 
Hypoalbuminemia 
Anemia—Erythropoietin effects on retina 
Hyperlipidemia 
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      PRECLINICAL RETINOPATHY 
In patients with Type 2 diabetes, it is more difficult to 
determine the interval between the development of diabetes and the 
development of retinopathy because it is believed that 4 to 7 years 
generally elapse between the onset of non-insulin dependent diabetes and 
its diagnosis. 
There is now ample evidence that functional and anatomic 
changes occur before the onset of vascular lesions in both types of 
diabetes. In the International Diabetic Retinopathy classification this 
phase corresponds to stage ‗0‘. Diabetic patients without retinopathy  
generally do not have any specific visual symptoms. Nevertheless, subtle 
defects in neurosensory retinal function have been demonstrated by 
sensitive testing methods, including decreased blue -yellow color 
perception and contrast sensitivity. In addition, the oscillatory amplitudes 
on the b-wave of electroretinogram (ERG) may be reduced. Mulifocal 
ERG and short-wavelength, and white-on-white perimetry testing reveal 
regional depression of retinal function in diabetic patients before the 
onset of vascular lesions .These tests indicate dysfunction of the inner 
retina, especially bipolar, amacrine, and ganglion cell neurons. Nerve 
fiber layer defects may also be detected by red free photography or 
scanning laser ophthalmoscopy in diabetic patients with minimal or no 
vascular lesions. Together, these findings provide strong evidence that 
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retinal function may be altered prior to the onset of vascular lesions and 
that diabetic retinopathy is not strictly a vascular disease. 
Experimental studies have demonstrated increased neural cell 
injury within 1 month of diabetes, long before the onset of typical 
vascular lesions. This accelerated cell death results in loss of the inner 
plexiform layers and ganglion cell, with retinal thinning. Recently studies 
have revealed loss of cholingergic and dopaminergic amacrine cells, 
remodeling of dendrites, and reduction of essential proteins of synapses 
as early neurodegenerative changes in diabetic retinopathy. Together, 
these subtle cellular changes may contribute to reduced oscillatory 
potentials in the ERG. Optic nerve axon size also decreases as part of the 
degenerative response of neural tissue to the metabolic stress of diabetes. 
The cause of these degenerative processes is highly complex but may 
include loss of neurotrophins (insulin, brain-derived neurotrophic factor), 
excess nutrients (glucose, amino acids, and lipids), inflammation, and 
excitotoxicity. Muller cells and astrocytes control glutamate metabolism, 
so glutamate accumulation in the extracellular fluid between neurons and 
glia implies that glial cells are defective, and the clearance of retinal 
glutatmate is impaired in experimental diabetes. Glutamate is a well-
recognized cause of neuronal cell death in cerebral ischemia (glutamate 
excitotoxicity). 
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Vascular changes that begin shortly after the onset of insulin-
deficient diabetes include delayed white blood cell migration in  
perifoveal capillaries , increased blood–retina barrier permeability , and 
increased retinal blood flow compare to non-diabetic control subjects 
.These findings suggest that vascular autoregulation is impaired before 
clinically evident vascular lesions appear.  
Thus, while this early phase of diabetic retinopathy appears to 
be innocuous from a clinical standpoint, numerous cellular and metabolic 
processes are active that lead to the development of clinically evident 
nonproliferative diabetic retinopathy (NPDR). Indeed, a recent 
demonstration that retinal flavoprotein fluorescence increases in diabetic 
patients before the onset of visible retinopathy is strong evidence for 
early onset of metabolic dysregulation. 
While it is reassuring that patients with diabetes may have no 
visible retinopathy, the absence of microaneurysms or hemorrhages 
should not lead to complacency on the part of patients or physicians. In 
fact, aggressive control of the metabolic and systemic cardiovascular risk 
factors known to exacerbate retinopathy onset and progression provides 
an ideal opportunity to prevent vision-threatening changes. 
Patients who have not developed retinopathy should have a 
treatment strategy designed to optimize the chance to maintain vision. 
These patients with healthy appearing retinas and good vision represent 
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the greatest therapeutic opportunity, particularly in light of the emerging 
diabetes epidemic. 
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      Preclinical Retinopathy 
 
S
ymptoms 
Clinical Signs Abnormal Test 
Results 
Histopatholo
gy 
Cellular 
Events 
Usually 
none 
Norma l 
appearing 
Retina 
Color 
perception: 
decreased 
blue-yellow 
sensation 
activation 
(deuteranomal
y) 
 
ERG: 
decreased 
oscillatory 
potential 
amplitudes 
 
Visual field 
defects 
 
Vitreous fl 
uorometry: 
increased 
blood–retina 
barrier 
permeability 
Neural cell 
apoptosis 
Microglial 
cell 
Activation 
 
 
 
 
 
 
 
Nerve fiber 
layer loss 
 
Glial cell 
dysfunction: 
increased 
glutamate 
Decreased 
vascular tight 
junctions 
 
 
 
 
Vascular 
basement 
membrane 
thickening 
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NONPROLIFERATIVE DIABETIC RETINOPATHY 
NPDR is defined and staged by ophthalmoscopic features such 
as vascular lesions, including microaneurysms, intraretinal hemorrhages, 
and vasodilation. The definitions (nonproliferative and proliferative) are 
useful clinically because they permit evaluation of visible ocular risk 
factors for moderate and severe visual loss. The specific sequence of 
cellular events that lead to the features of NPDR remain uncertain 
because they occur below the resolution Although pericytes and 
endothelial cells clearly undergo programmed cell death (apoptosis), it is 
unproven whether pericytes are uniquely susceptible to diabetes. The 
original light microscopic study of trypsin digest preparations in which 
the neural retina is removed to reveal the vascular network did not 
indicate the specific anatomic site from which the photos were taken, 
gave no statistical analysis of pericyte dropout or other morphologic 
lesions, and did not determine whether pericyte loss occurred in areas 
without microaneurysms. Another study questioned whether pericytes are 
lost first or preferentially in diabetic retinopathy. 
  Therefore, while pericytes undoubtedly change in diabetic 
retinopathy, they do not appear to be the earliest cellular defects, and the 
specific functional consequences are still unclear. Cotton-wool spots have 
been considered to represent focal infarcts of the nerve fiber layer due to 
local microvascular occlusion. However, cotton wool spots have also 
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been described in diabetic persons without clinical or fluorescein 
angiographic evidence of vascular occlusion and may resolve without 
detectable nerve fiber layer loss. Hence, it is likely that the loss of axonal 
transparency that appears as retinal whitening results from impaired 
axonal metabolism and axonal transport, particularly in patients with 
poorly controlled diabetes. 
  Some young  patients (<45 years old) exhibit focal 
depressions in the macular reflex, the ―retinal depression sign‖. This 
sign results from small retinal depressions that reflect light away from the 
observer so that the macula appears slightly darker than the surrounding 
retina. The feature is best observed by slit-lamp biomicroscopy and is 
also noted on fundus photographs, particularly with red-free filters. It is 
more easily recognized in young patients who have a bright foveal reflex 
than in older persons. The thinning may result from macular ischemia 
and/or nonischemic neuroretinal degeneration (apoptosis). This finding 
may contribute to paracentral scotomas and may be confused with 
epiretinal membranes or macular edema. 
  The cellular and biochemical events that results in vascular 
lesions in diabetic retinopathy are uncertain in humans and complex. 
While it is clear that intensive treatment of diabetes in humans or animals 
significantly delays the progression and onset of retinopathy, it is not 
known whether the  retinopathy development represents a direct result of 
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insulin resistance or insulin deficiency, a consequence of hyperglycemia, 
or another metabolic derangement associated with diabetes, such as 
increased lipids. The metabolic pathways that have an association with 
diabetic retinopathy include activation of the polyol pathway, 
nonenzymatic glycosylation, and activation of the s isoform of protein 
kinase C (PKC-s). Increased glucose metabolism via the polyol pathway , 
has also been considered to account for diabetic retinopathy and 
peripheral neuropathy. The hypothesis suggests that increased glucose 
metabolism via this pathway results in the accumulation of sorbitol, 
reduction of myo - inositol, and/or reduction in activity of sodium-
potassium-ATPase, which may account for vascular dysfunction. Aldose 
reductase is a key enzyme in the polyol pathway. However, specific 
vascular functional or neuronal abnormalities, such as barrier breakdown 
or capillary closure, have not been fully explained by this hypothesis. 
Another theory for the development of diabetic retinopathy 
involves vascular damage by advanced glycosylation end products 
(AGEs). According to the concept of nonenzymatic glycosylation , sugar 
molecules bond covalently to reactive molecules and cause alterations in 
the functions of proteins, nucleic acids, and cells, such as macrophages. 
This reaction gives rise to the glycohemoglobin (hemoglobin A1c) test, 
which measures integrated glucose levels over 3 months. Cross-linking of 
long-lived proteins such as collagens has been proposed to due to 
31 
 
nonenzymatic glycosylation, which are found in vitreous and vascular 
basement membranes. Collagen cross-linking may decrease the turnover 
of collagen and may contribute to vitreous collagen contraction and allow 
for basement membrane thickening . Advanced glycation end products 
increase in Muller cells in experimental diabetes, and a AGE 
receptor(soluble) that blocks its activation, decreases cell death of 
neurons. 
Thus, in spite of a likely role, there is no experimental evidence 
that demonstrates that excess glucose alone is necessary or sufficient to 
cause retinopathy or other complications in diabetes. Another metabolic 
mechanism involves a specific molecule in signal transduction cascades. 
Protein kinase C adds phosphate groups to serine or threonine residues of 
cytoplasmic proteins. This enzyme also phosphorylates other proteins in 
the signal transduction cascade of VEGF and histamine, and is associated 
with alterations in retinal blood flow and blood–retina barrier breakdown. 
An oral agent that inhibits PKC-s activity (ruboxistaurin, Eli Lilly Co)  
reduced the risk of visual loss in persons with diabetic macular edema 
and visual acuity , however it did not bring about any change in the risk 
of developing neovascularization in diabetic patients with severe non 
proliferative diabetic retinopathy. VEGF production by nonvascular 
retinal cells, including astrocytes, Muller cells, and ganglion cells, 
indicating that increased vascular permeability may be the consequence 
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of vasoactive compounds originating in the neural retina acting 
secondarily on the microvasculature. This observation is further evidence 
that diabetic retinopathy may not be a primary vascular disease. 
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Diabetes 
Hyperglycemia 
Insulin deficiency 
 
Expression of vasoactive factors 
(VEGF/VPF, histamine) 
by neurons, glial cells 
 
PKC-s activation 
  
 
 
  Endothelial cell proliferation                 Vascular permeability via                      
                                                  action on endothelial cell  
                                                  tight junction and/or     
                                                  increased transcytosis  
 
 
         Microaneurysms                                            Macular edema     
Possible mechanism for development of nonproliferative 
diabetic    retinopathy.    
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      Nonproliferative Diabetic Retinopathy 
Sympt
oms 
Clinical Signs Abnormal 
Test Results 
Histopatholog
y 
Cellular 
Events 
None, 
Blurre
d 
v
Vision
, or 
g
Glare 
Retinal 
vasodilation 
Microaneurys-
m 
Cotton-wool 
spots 
 
 
 
 
 
Intraretinal 
Hemorrhages 
 
 
IRMAs, 
Venous 
beading 
Retinal 
depression 
Sign 
 
Intravenous 
fluorescein 
angiography
: 
vascular 
leakage 
and 
occlusion 
ERG: 
depressed 
oscillatory 
amplitudes 
 
Increased 
retinal 
blood flow 
 
 
Visual field 
Defects 
Microaneurys
ms, 
intraretinal 
hemorrhages 
in 
nerve fiber 
layer 
and outer 
plexiform 
layer 
 
 
 
Cytoid bodies, 
nerve fiber 
layer 
swelling 
 
Neuronal loss 
and 
degeneration, 
lipid exudates 
and 
extracellular 
edema in outer 
plexiform 
layer; 
nerve fiber 
layer 
atrophy 
Glial cell 
occlusion 
of capillaries 
 
Increased 
VEGF 
expression 
by 
neurons 
and 
glial cells 
 
 
 
 
 
Vascular 
cell 
Apoptosis 
 
 
Glial cell 
activation 
and 
macropha
ge 
infi 
ltration 
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     DIABETIC MACULAR EDEMA 
The physiologic factors that govern the development of DME 
are similar to those involved in tissue edema elsewhere in the body, and 
understanding the pathophysiology of DME allows construction of a set 
of risk factors and treatment principles for DME. 
Starling‘s law of the capillary states that edema formation in 
tissues from fluid flux across the capillary wall is related to the 
hydrostatic pressure gradient (blood pressure minus tissue pressure) less 
the oncotic pressure that draws water into the vessels. This relationship 
has recently been shown to also operate in the retina for DME. That is, 
increased intravascular hydrostatic pressure from hypertension or 
intravascular fluid overload drives fluid across the vascular wall and leads 
to increased fluid accumulation in the macula. The oncotic force that 
pulls water from tissue into capillaries is determined by the plasma 
albumin concentration, so when albumin levels decrease below 3.0 
mg/dL, the oncotic pull is sufficiently diminished to contribute to tissue 
edema. Patients with diabetes frequently have impaired Starling‘s 
equilibria. The clinical risk factors for DME include increased 
intravascular volume due to hypertension, fluid overload (congestive 
heart failure and renal failure) and hypoalbuminemia from diabetic 
nephropathy. 
36 
 
Venous tortuosity and dilation are frequently noted in patients 
with progressive retinopathy. The physiologic basis of this feature owes 
to autoregulatory vasodilation of arterioles that causes intravascular 
pressure in the arterioles to decrease and that in the venules to increase, 
according to Poiseuille‘s Law. The increased hydrostatic pressure also 
leads to greater blood vessel length and tortuosity, per LaPlace‘s Law. 
Serial observations in patients with diabetes have shown that retinal 
vascular diameter and length increase prior to the onset of DME and 
improve following macular photocoagulation for DME and after 
panretinal photocoagulation for proliferative diabetic retinopathy (PDR). 
In addition to altered autoregulation of vascular flow, the 
intrinsic integrity of the retina-blood barrier is also impaired. Studies with 
vitreous fluorometry in humans show that breakdown of the inner retina-
blood barrier (as a result of tight junctions between vascular endothelial 
cells) predominates over changes in the outer barrier (tight junctions 
between retinal pigment epithelial cells) in early DME . The outer barrier 
breaks down in patients with chronic DME. The proteins that comprise 
the tight junctions between vascular endothelial cells are reduced in early 
experimental diabetes, and this may account for increased vascular 
permeability. As such, the hemodynamic abnormalities in the retina are 
analogous to those that occur in the kidney in early diabetes; that is, 
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increased renal blood flow and increased glomerular permeability, with 
resultant albuminuria. 
Other factors may also aggravate the overall severity of 
retinopathy. For example, hyperlipidemia has been associated with an 
increased risk of hard exudates and macular edema, and anemia is 
associated with worsening of retinopathy in general. Anemia may impair 
oxygen delivery to the retina. In addition, erythropoietin may serve as a 
trophic factor for retinal cells and its deficiency might aggravate retinal 
cell death. Conversely, excessive intraocular erythropoietin levels may 
contribute to the development of DME and PDR. 
Together, these risk factors give rise to principles of DME 
treatment, including improving metabolic control, blood pressure, fluid 
overload, anemia, and hyperlipidemia. 
Microaneurysms are the most characteristic ophthalmoscopic 
features of diabetic retinopathy. They occur throughout the posterior pole 
and are often first noted temporal to the macula. Their importance lies in 
their association with the retinopathy severity and as sources for leakage 
of fluid and lipid transudates. 
Histologically, they are outpouchings of the capillaries, with 
focal endothelial cell proliferation and pericyte loss, often adjacent to 
areas of nonperfusion. The factors that contribute to microaneurysm 
formation likely include structural features (loss of supporting pericytes 
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and astrocytes), hemodynamic alterations (increased capillary intramural 
pressure), and local production of vasoproliferative factors, such as 
VEGF. Like cotton wool spots, retinal thickening, and hemorrhages, 
microaneurysms can wax and wane through the course of retinopathy. 
Understanding the pathophysiology of DME allows 
construction of a set of systemic risk factors, such as poor glycaemic  
control, systemic arterial hypertension, increased lipid levels, and low 
albumin levels. 
 
 
Mechanisms of Diabetic Macular Edema 
Poor glycaemic control 
Increased hydrostatic pressure 
Hypertension 
Intravascular fluid overload (congestive heart 
failure, renal failure) 
Decreased colloid oncotic pressure 
Low albumin levels 
High lipid levels 
Anemia 
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      PROLIFERATIVE DIABETIC RETINOPATHY 
PDR, characterized by new vessels on the optic nerve head, 
retina, and/or iris, may be an aberrant attempt to alleviate hypoxia in eyes 
with severe capillary closure or other retinal ischemia. The new vessels 
grow perpendicular to the plane of the retina into the scaffolding provided 
by the vitreous cortex, typically from venules at the junction of perfused 
and nonperfused retina. In contrast to normal retinal vessels, which are 
ensheathed by intact astrocytes, neovascularization is associated with 
reactive glial cells   which do not allow endothelial cell tight junctions to 
form completely, with resultant hyperfl-uorescence noted on fluorescein 
angiography. PDR, first involves angiogenesis (neovascularization), 
followed by macrophage infiltration, remodeling of the vessels, with 
subsequent fibrosis, and eventual replacement of the vascular tissues by 
collagen. 
The natural history of untreated PDR includes fibrosis of the 
neovascularization, inducing traction on the retina. Subsequent 
contraction may induce preretinal hemorrhage, vitreous hemorrhage, and 
traction retinal detachment. Panretinal photocoagulation alters the healing 
response by reducing the neovascular proliferation, and inducing 
quiescence. 
The cellular events that lead to neovascularization may include 
retinal hypoxia, elaboration of factors that stimulate endothelial cell 
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proliferation, macrophages and vitreous contraction. Numerous factors 
have been implicated in the pathogenesis of retinal new vessels, including 
erythropoietin, growth hormone, basic fibroblast growth factor (bFGF), 
insulin-like growth factor 1 (IGF-1), and VEGF. Together, these ―growth 
factors,‖ cytokines, and cells comprise an inflammatory response. As 
noted above, VEGF is produced by cells in the neurosensory retina and 
acts by specific endothelial cell surface receptors to induce 
neovascularization. VEGF levels are increased in the vitreous of eyes 
with new vessels and subsided after panretinal photocoagulation. 
Inhibition of VEGF action by antisense oligonucleotides that 
inhibit VEGF messenger RNA or by antibodies that bind the protein 
before it can activate its receptors reduces neovascularization. After 
panretinal photocoagulation or intravitreal bevacizumab injection, VEGF 
levels diminish and those of connective tissue growth factor (CTGF) 
increase, changing the wound healing response from angiogenesis to 
fibrosis. 
VEGF production is not unique to diabetic retinopathy, and is 
also increased in retinopathy of prematurity and other ocular neovascular 
processes, as well as in physiologic conditions (menstruation and wound 
healing) and in pathologic vascularization (tumors) throughout the body. 
The control of retinal angiogenesis is complex,and the molecular puzzle 
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is still being unraveled. Vitreous collagen crosslinking via nonenzymatic 
glycosylation may contribute to vitreous contraction. 
Diabetic retinopathy involves both vascular and neural 
elements of the retina from the early stages of diabetes through the 
development of PDR. Improved means of preventing visual loss in 
diabetes depend on a better understanding of the underlying mechanisms 
and the altered relationships between the neural retina and blood vessels. 
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                Hypoxia of retinal neurons, glial cells        
                          
Release of factors that increase vascular permeability 
and endothelial cell mitosis (VEGF, probably others) 
 
Proliferation of new vessels through 
internal limiting membrane 
 
Growth of new vessels into posterior vitreous cortex 
                      
Glial cell proliferation* → epiretinal membranes 
 
Contraction of vitreous and traction on new vessels 
 
Vitreous hemorrhage, traction retinal detachment 
Mechanisms of proliferative diabetic retinopathy 
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     Proliferative Diabetic Retinopathy 
 
Symptom
s 
Clinical Signs Abnormal Test 
Results 
Histopatholog
y 
Cellular 
Events 
None, 
reduced 
vision, 
nyctalopi
a 
or  
floaters 
Retinal signs: 
neovascularizati
on 
of optic disc, 
retina 
and/or iris, 
retinal 
vasodilation 
beading, and 
IRMAs 
 
 
 
 
 
Vitreous signs: 
vitreous cells, 
contraction, and 
opacification of 
posterior hyaloid 
face, partial 
posterior 
vitreous 
detachment 
with epiretinal 
membranes, and 
traction retinal 
detachment 
 
Intravenous 
fluorescein 
angiography: 
severe 
capillary closure 
and 
hyperfl -
uorescence 
of 
neovascularizati
on 
with leakage 
 
 
 
 
Dark daptation: 
impaired 
Ultrasonography
: 
partial posterior 
vitreous 
detachment 
with vitreoretinal 
adhesions; 
retinal 
detachment 
Glial cell 
proliferation 
and epiretinal 
membranes 
 
Endothelial 
cell 
Proliferation 
 
Intraretinal 
Haemorrhage 
 
Cystoid 
macular 
Edema 
 
Neuronal 
loss, 
retinal 
detachment 
 
Vitreous 
collagen 
cross-
linking 
 
 
Endothelial 
cell mitosis 
 
Glial cell 
Proliferatio
n 
 
Occluded 
Capillaries 
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      CLASSIFICATION OF RETINOPATHY 
Historically, diabetic retinopathy has been classified based on 
ophthalmoscopic findings, ranked into a stepwise scale from no 
retinopathy through various stages of non-proliferative or pre-
proliferative disease to advanced proliferative disease ranked on a 
continuous scale from no retinopathy to advanced proliferative diabetic 
retinopathy(PDR) with Non-Proliferative diabetic retinopathy(NPDR) 
falling somewhere in the middle of the continuum. However, this grading 
may not accurately reflect functionally severe disease since maculopathy 
with severe visual loss may occur in the presence of moderate 
ophthalmoscopic signs. 
There are two different systems of classification for diabetic 
retinopathy. One is designed for the ophthalmologist and covers all the 
aspects of diabetic retinopathy. The other classification system is aimed 
for use in population screening which identifies four different types of 
presentation of fundus disease namely, Retinopathy, maculopathy, 
photocoagulation and unclassifiable. 
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      ETDRS 
 
has classified NPDR into mild, moderate, severe 
and very severe and PDR into early PDR and high-risk PDR. This is as 
follows: 
 
A. Mild NPDR: Presence of at least one microaneurysm, definition not 
met for B, C, D, E, or F. 
 
B. Moderate NPDR: Hemorrhages and/or microaneurysms, presence of 
soft exudates, venous beading, IRMA definitely present, definition not 
met for C, D, E, or F. 
 
C. Severe NPDR: Hemorrhages and/or microaneurysms in all four 
quadrants, or venous beading in two or more quadrants, or IRMA in at 
least one quadrant, definition not met for D, E, or F. 
 
D. Very severe NPDR: Any two or more of the changes seen in severe 
NPDR, definition not met for E, or F. 
 
E. Early PDR: Presence of new vessels, definition not met for F. 
 
46 
 
      F. High-risk PDR: Includes any of the following 
characteristics - neovascularization of disc (NVD) > 1/3
 rd
 to 1/4
 th
 disc 
diameter, NVD < 1/3
 rd
 to 1/4
 th
 disc diameter with vitreous/pre-retinal 
hemorrhage, NVE with vitreous/pre-retinal hemorrhage. High-risk 
characteristics (HRC) were defined by DRS, as the patient, if not treated 
urgently, is at a high risk of severe visual loss 
                                 
      G.  Diabetic maculopathy: 3 types-focal Maculopathy- 
presence of micro aneurysms, hemorrhage, macular edema and hard 
exudates arranged in circinate pattern. Diffuse maculopathy- presence of 
diffuse retinal edema and thickening. Ischemic maculopathy- marked 
visual loss with micro aneurysms, hemorrhage, mild or no macular edema 
 
H. Advanced eye disease: persistent vitreous hemorrhage, 
Tractional retinal detachment, and Neovascular glaucoma. 
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COMPLICATIONS OF DIABETIC RETINOPATHY 
Diabetic retinopathy can be further a cause for a variety of 
ocular complications.Thes can be divided into specific and non-specific 
Specific complications: 
-Retinal detachment 
-Rubeosis iridis 
-Cataract 
-maculopathy 
-papillopathy 
Non-specific complications 
-Glaucoma 
-Retinal vein occlusion 
-Optic disc   swelling 
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THE THYROID GLAND 
 
Anatomy of the thyroid gland  
The thyroid ( Greek thyreos, shield, plus eidos, form ) is a 
highly vascular, brownish-red gland located anteriorly in the lower neck, 
extending from the level of the fifth cervical vertebra down to the first 
thoracic vertebra. The gland consists of a right and left part which are 
joined to each other by the isthmus. A third pyramidal lobe may some 
times project from the isthmus or one of the lobes. 
Although weight of the thyroid varies, it averages 25-30 g in 
adults. Four parathyroid glands, which produce parathyroid hormone, are 
located posterior to each pole of the thyroid.
 
The thyroid gland has two capsules covering it. The true 
capsule is formed by condensation of the connective tissue of the gland 
while the false capsule is derived from the pretracheal layer of deep 
cervical fascia. 
The fascia surrounding the gland firmly attach  it to the 
cartilage rings. This attachment of the gland to the laryngoskeleton is 
responsible for movement of the thyroid gland and related structures 
during . The recurrent laryngeal nerve is closely related to the inferior 
thyroid artery and it is important to protect this nerve during a 
thyroidectomy. The nerves, one on the left and one on the right, arise 
from the vagus. It supplies the laryngeal muscles. 
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On the right hand side, the nerve  hooks around the subclavian 
artery. On the left, the nerve passes around aortic arch. The nerves pass 
beneath the Berry's ligament on their way to entering the larynx. 
 
               Histology of Thyroid gland:  
The capsule of the thyroid sends multiple septae into the 
substance of the gland dividing it into lobes and lobules. The structural 
unit of the gland are follicles which are formed by a layer of simple 
epithelium enclosing a colloid filled cavity. This colloid contains the 
precursor of thyroid hormones, an iodinated glycoprotein called 
iodothyroglobulin. The size of these follicles vary and they are 
surrounded by dense plexuses of fenestrated capillaries, lymphatics, and 
sympathetic nerves.  
There are two major types of cells in the epithelium, the 
principal cells (ie, follicular) which secrete the colloid ( 
iodothyroglobulin) and parafollicular cells (ie, C, clear, light cells) which 
produce calcitonin. Parafollicular cells lie adjacent to the follicles within 
the basal lamina.
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Vascular anatomy of the thyroid gland 
Three arteries usually supply the thyroid gland. The superior 
and inferior thyroid arteries are the main arteries whereas thyroidea ima is 
a less consistent one. These arteries freely anastomose with one another, 
ipsilaterally and contralaterally. The superior thyroid artery which is a 
branch of the external carotid artery is located superiorly and enters the 
gland at the two upper poles. The artery is closely related to the external 
laryngeal nerve, a branch of the superior laryngeal nerve. The inferior 
thyroid artery arises from the thyrocervical trunk  
It supplies the posterior aspect of the gland. The Thyroidea Ima 
Artery of Neubauer is a lower thyroid artery that may arise from the 
brachiocephalic artery, the arch of the aorta, or internal mammary 
arteries. As it often runs in front of the aorta and over the isthmus, it is 
liable to be cut during a tracheostomy. . The vessel is usually single but 
can be a paired structure.  
Venous and lymphatic drainage:  
Three pairs of veins drain the gland. The superior thyroid vein 
accompanies the superior thyroid artery and becomes a tributary of the 
internal jugular vein (IJV). The middle vein follows a direct course 
laterally into the IJV. The two inferior thyroid veins do not follow a 
uniform path . The right passes anterior to the innominate artery and 
drains into the right brachiocephalic vein or anterior to the trachea to the 
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left brachiocephalic vein. On the left side, it drains in to the left 
brachiocephalic vein. Occasionally, both the  inferior thyroid veins form a 
common trunk called the thyroid ima vein, which flows into the left 
brachiocephalic vein.   
The gland has extensive lymphatic drainage and the immediate 
drainage occurs to the periglandular nodes; to the prelaryngeal, 
pretracheal, and paratracheal. From here it goes to the mediastinal lymph 
nodes. 
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      PHYSIOLOGY OF THYROID GLAND 
The principal hormone secreted by the thyroid are T3, T4 and  
calcitonin. Both T3 and T4 are iodine – containing aminoacids. Small 
amounts of reverse triiodothyronine (RT3) are also formed, but RT3 is 
inactive.T3 is more active than T4. 
Thyroglobulin (Tg) : 
T
4 
and T
3 
are synthesized in the colloid by iodination and 
condensation of tyrosine molecules bound in peptide linkage in Tg. This 
glycoprotein is made of two subunits and has a molecular weight of 
660,000. It has 123 tyrosine residues, but only four to eight of these are 
normally incorporated into thyroid hormones. Tg is synthesized in the 
thyroid cells and secreted into the colloid by exocytosis of granules that 
also contain thyroid peroxidase (TPO). The hormones remain bound to 
Tg until secreted. When they are secreted, colloid is ingested by thyroid 
cells, the peptide bonds are hydrolyzed, and free T
4 
and T
3 
are discharged 
into the capillaries.  
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                            Properties of thyroid hormones 
 
Hormone 
Property  
T
4 
 T
3 
 
Serum concentrations  
Total hormone  3.2 – 
12.6 microg/dl  
60-181 
ng/dl  
Fraction of total 
hormone in the free form  
0.025%  0.2-0.3 
%  
Free hormone   21 x 10
-12 
M  
6 x 10
-12 
M  
Serum half-life  5-7 d  .5 to 1 d  
Fraction directly 
produced by the thyroid  
100%  20%  
Rate of 
production, including 
peripheral conversion  
90-100 
μg/d  
30-35 
μg/d  
Intracellular 
hormone fraction  
20%  70%  
Relative 
metabolic potency  
0.3  1  
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 THYROID HORMONE SYNTHESIS  
Iodine metabolism and transport  
The primary function of the thyroid gland is to produce the 
amount of thyroid hormone necessary to meet the demands of the 
peripheral tissues. This requires the daily thyroidal uptake of sufficient 
iodide and its oxidation by thyroid peroxidase enzyme  to allow the 
synthesis of approximately 85 micrograms of T4, which is nearly  65% 
iodine by weight. This requires the synthesis of a 660-kd glycoprotein 
homodimer, Tg. Tg contains specific tyrosine residues that are then 
iodinated at the apical portion of the thyroid cell to form mono- and 
diiodotyrosine (MIT and DIT)  
TPO-catalyzed coupling of two molecules of DIT, or one of 
DIT and one of MIT, leads to formation of T4 and T3, respectively, which 
are then stored as colloid, still as part of the Tg molecule. Pinocytosis of 
stored colloid leads to the formation of phagolysosomes, the colloid 
droplets in which Tg is digested, releasing T4, T3, DIT, and MIT as the 
droplet is translocated toward the basal portion of the cell. Thyroxine and 
T3 exit the cell into the capillaries, and DIT and MIT are deiodinated by 
an iodotyrosine deiodinase to allow recycling of the iodide to iodinate 
newly synthesized Tg. 
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Iodine deficiency is prevalent in many high altitude regions and 
in parts of central Africa, central South America, and northern Asia. 
According to the W.H.O there are nearly 2 billion iodine-deficient people 
in the world, based on urinary excretion data. In areas of relative iodine 
deficiency, there is an increased prevalence of goiter and, when 
deficiency is severe, hypothyroidism and cretinism. The recommended 
average daily intake of iodine is 150μg/d for adults around 100 for 
children and 180 to 200 μg per day for pregnant women. 
 
TSH ACTION 
TSH, secreted by the anterior pituitary, is a 31-kDa hormone 
with alpha and a beta subunit, the alpha subunit is common to the other 
glycoproteins hormones (LH, FSH, hCG) whereas beta subunit is unique 
to TSH. TSH regulates functions of the thyroid gland through the TSH- 
Receptor, a seven-transmembrane G protein-coupled receptor (GPCR). 
The TSH-R is coupled to the alpha subunit of stimulatory G protein 
(Gso), which  activates adenyl cyclase, leading to increased production of 
cyclic AMP. TSH also stimulates phosphatidylinositol turnover by 
activating phospholipase C. The functional role of the TSH-R is 
exemplified by the consequences of naturally occurring mutations. 
Recessive loss-of-function mutations cause thyroid hypoplasia and 
congenital hypothyroidism. Dominant gain-of-function mutations cause 
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sporadic or familial hyperthyroidism that is characterised by goiter, 
thyroid cell hyperplasia and autonomous function. Most of this activating 
mutations occur in the transmembrane domain of the receptor. 
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FACTORS INFLUENCING THYROID HORMONE 
SYNTHESIS AND RELEASE : 
Hypothalamic-Pituitary-Thyroid Axis  
The thyroid gland participates with the hypothalamus and 
pituitary gland in a classic feedback control loop. In addition, there is an 
inverse relationship between the glandular organic iodine level and the 
rate of hormone formation. Such auto regulatory mechanisms serve to 
stabilize the rate of hormone synthesis despite fluctuations in the 
availability of iodine. Stability in hormone production is achieved, in 
part, because the large intraglandular store of hormone buffers the effect 
of acute increases or decreases in hormone synthesis. Auto regulatory 
mechanisms within the gland, in turn, tend to maintain the constancy of 
the thyroid hormone pool.  
Finally, the hypothalamic-pituitary feedback mechanism senses 
variations in the availability of free thyroid hormones, however small, 
and acts to correct them. There is a close relationship between the 
hypothalamus, the anterior pituitary gland, the thyroid gland, and still 
higher centers in the brain, with the function of the entire complex being 
modified in a typical negative-feedback manner by the availability of the 
thyroid hormones. Additional hormones and neuropeptides also influence 
this axis. 
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 EXOGENOUS AND ENDOGENOUS FACTORS THAT 
INFLUENCE THYROID   HORMONE ECONOMY: 
1) Pregnancy and maternal- fetal interactions 
2) Glucocorticoids 
3) Gender and gonadal steroids 
4) Growth hormone 
5) Environmental temperature 
6) Nutrition 
7) Effects of illness                                                                               
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THYROID HORMONE TRANSPORT AND METABOLISM 
Serum binding proteins  
T4 is secreted from the thyroid gland in about twenty fold excess over 
T3. Both T3 and T4 are bound to plasma proteins, including thyroxine-bimding 
globulin (TBG); transthyretin (TTR) and albumin. These proteins increase the 
pool of circulating hormone, delay renal clearance of the hormone, and may 
modulate hormone delivery to select tissue sites. The concentration of TBG is 
relatively low (1-2 mg/dl) but because of its high affinity for thyroid hormones 
(T4 > T3), it carries about 80% of the bound hormones. In comparison albumin 
has relatively low affinity for thyroid hormones but has a high plasma 
concentration (~3.5 g/dl), and it binds upto 10% of T4 and 30% of T3. TTR 
carries about 10% of T4 but little T3. When the effects of the various binding 
proteins are combined, approximately 99.98% of T4 and 99.7% of T3 are 
protein-bound. Because T3 is less tightly bound then T4, the fraction of 
unbound T3 is greater than unbound T4, but there is less unbound T3 in the 
circulation because it is produced in smaller amounts and cleared more rapidly 
than T4. The unbound, or free concentrations of the hormones are ~2 X 10
-11
M 
for T4 and ~6 X 10
-12
M for T3, which roughly correspond to the thyroid 
hormone receptor bindinf contants for these hormones. The unbound hormone 
is thought to be biologically available to tissues, although the discovery of 
megalin as a cellular transporter of protein-bound steroids raises the possibility 
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of distinct transport systems for bound and unbound hormones. Nonetheless, the 
homeostatic mechanism that regulate the thyroid axis are directed toward 
maintenance of normal concentrations of unbound hormones.  
               Deiodinaes 
T4 may be thought of as a precursor for the more potent T3. T4 is 
converted to T3 by the deiodinase enzymes. Type 1 deiodinase, which is located 
primarily in thyroid, liver, and kidney has a relatively low affinity for T4. Type 
2 deiodinase has a higher affinity for T4 and is found primarily in the pituitary 
gland, brain, brown fat, and thyroid gland. Expression of type 2  deiodinase 
allows it to regulate T3 concentrations locally, a property that may be important 
in the context of levothyroxine (T4) replacement. Type 2 deiodinase is also 
regulated by thyroid hormone; hypothyroidism induces the enzyme, resulting in 
enhanced T4→T3 conversion in tissues such as brain and pituitary. T4→T3 
conversion is impaired by fasting, systemic illness or acute trauma, oral contrast 
agents, and a variety of medications (e.g. propylthiouracil, propranolol, 
amiodarone, glucocorticoids). Type 3 deiodinase inactivates T4 and T3 and is 
the most important source of reverse T3 (rT3). Massive hemangiomas that 
express type 3 deiodinase are rare cause of hypothyroidism in infants. 
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        THYROID HORMONE ACTION: 
Circulating thyroid hormones enter cells by passive diffusion and via 
the monocarboxylate 8 (MCT8) transporter. After entering cells, thyroid 
hormones act primarily through nuclear receptors, although they also stimulate 
plasma membrane and mitochondrial enzymatic responses. Thyroid hormones 
bind with high affinity to nuclear thyroid hormone receptors (TRs) α and β.TR 
α is particularly abundant in brain, kidney, gonads, muscle, and heart, whereas 
TR β expression is relatively high in the pituitary and liver. However, structural 
differences in the ligand binding domains provide the potential for developing 
receptor-selective agonists or antagonists. T
3 
is bound with 10–15 times greater 
affinity than T
4
, which explains its increased hormonal potency. Though T
4 
is 
produced in excess of T
3
, receptors are occupied mainly by T
3
, reflecting T
4 
→T
3 
conversion by peripheral tissues, greater T
3 
bioavailability in the plasma, 
and receptors' greater affinity for T
3
. 
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      EFFECTS OF THYROID HORMONES :  
Many of the various effects of thyroid hormones in the body are 
secondary to stimulation of oxygen consumption ( calorigenic action ). The 
hormones also affect growth and development in mammals, help regulate lipid 
metabolism, and increase the absorption of carbohydrates from the intestine. 
They also increase the release of oxygen from hemoglobin by increasing red 
cell 2,3-DPG. 
   
  
 
 
 
 
 
 
 
 
 
 
 
63 
 
             PHYSIOLOGIC EFFECTS OF THYROID HORMONES 
Target 
tissue 
Effect Mechanism 
Heart Chronotropic Enhances number and affinity of 
β-adrenergic receptors 
Heart Inotropic Increases responses to circulating 
catecholamines. Increases 
proportion of α-myosin heavy 
chain 
Adipose 
tissue 
Catabolic Stimulate lipolysis 
Muscle Catabolic Increase protein catabolism 
Skeletal 
system 
Developmental Promotes normal growth and 
skeletal development 
CNS Developmental Promote normal brain 
Lipoprotein Metabolic Increased number of LDL 
receptors 
Others Calorigenic Increases oxygen consumption 
metabolically active tissues 
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  EVALUATION OF THYROID DISORDERS  
Diseases of the thyroid gland almost always manifest themselves with 
symptoms resulting from either excessive or insufficient production of thyroid 
hormone. The thyroid disease is established on the clinical grounds and the 
functional disturbance is assessed by the metabolic state. The functional 
diagnosis of thyroid disease is based upon a carefully taken history, through 
search for the physical signs of hypo or hyperthyroidism and in an elegant 
appraisal of the results of the laboratory tests 
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CLINICAL FEATURES OF THYROID DISORDERS  
 
HYPOTHYROIDISM 
Symptoms  
Tiredness, Weakness, Dry skin  
Feeling cold, Hair loss  
Poor concentration and memory 
Constipation,  
Weight gain with poor appetite,  
Dyspnea  
Hoarse voice  
Menorrhagia  
(later oligomenorrhea or amenorrhea)  
Paresthesia , Impaired hearing 
Signs  
Dry coarse skin; cool extremities  
Puffy face, hands, and feet (myxedema)  
Diffuse alopecia  
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Bradycardia  
Peripheral edema  
Delayed tendon reflex relaxation  
Carpal tunnel syndrome  
Serous cavity effusions 
 
  HYPERTHYROIDISM 
  Symptoms 
  Hyperactivity,Irritability 
  Increased sweating 
  Fatigue and weakness 
  Palpitation 
  Oligomenorrhea and loss of libdo  
  Weight loss with increased appetite 
  Diarrhea, Polyuria 
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Signs 
Tachycardia, Atrial Fibrillation 
Tremor 
Goiter 
Warm moist skin 
Proximal myopathy 
Lid Retraction 
Gynaecomastia 
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        SUB CLINICAL HYPOTHYROIDISM 
Defined as an elevated TSH levels with normal free thyroxine levels
 
, 
among people without any history of  thyroid disorders .Subclinical 
hypothyroidism has a prevalence of around 5%. The prevalence is higher in the 
elderly and females. Above 60 years, the prevalence is nearly equal in males 
and females, with a combined prevalence of around 10%. Nearly 80% of these 
patients have anti thyroid anti bodies in their serum and their TSH values are 
usually less than 10mIU/ml. Before diagnosing SCH, other causes of an 
elevated TSH level, such as convalescence, variability in assay, presence of 
heterophile antibodies that can affect the results, and some cases of central 
hypothyroidism with biologically inactive TSH and thyroid hormone resistance, 
need to be ruled out. Autoimmune disordere of the thyroid are the most 
common cause of elevated TSH. Surgeries, radiation exposure and radio iodine 
therapy can also lead on to mild thyroid failure. SCH may develop in the post 
partum period and after episodes of silent and De Quervain‘s thyroiditis. 
 
 
 
 
 
69 
 
Defining the normal upper limit level for serum TSH level: 
Even though people with a TSH level between 3.0 and 5.0 mIU/L are 
more likely to have positive antithyroid antibodies and future thyroid disease, 
the lack of evidence for a benefit from levothyroxine therapy at these levels 
makes keeping the upper limit of TSH at 4.0 to 5.0 (depending on the 
laboratory) more reasonable. In the elderly population (>70 years) 
hypothyroidism need not be diagnosed even with TSH values up to 7 mIU/ml in 
the absence of anti-thyroid antibodies. Similarly normal TSH values for 
pregnancy are different. 
 
Screening for SCH: 
The American Thyroid Association recommends screening by 
measurement of serum TSH beginning at age 35 years and every 5 years 
thereafter.
 
The American College of Physicians acknowledges that treatment for 
subclinical thyroid dysfunction is controversial but suggests that screening to 
detect thyroid dysfunction may be indicated in women older than 50 
years.Screening is advised much more aggressively in the pregnant population 
due to the adverse effects of SCH on the fetus ans well as the outcome of the 
pregnancy.  
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           Adverse consequences of SCH  
Although studies have pointed to some adverse effects of SCH, no 
consensus exists as to the clinical importance of the adverse effects and the 
benefits of levothyroxine therapy, particularly for the 80% of patients with SCH 
who have a TSH of less than 10 mIU/L, because of the different levels of TSH 
and degrees of thyroid dysfunction in these studies.
 
 
           Progression to overt hypothyroidism 
The annual rate of progression of SCH to overt hypothyroidism is 
quite high (2.6%).This is even higher if thyroid peroxidase antibody is positive 
(4.3%). 
However some people do not show progression and some even show 
normalization of TSH values. People with a higher value of TSH (>10miu/l) 
show a higher rate of progression while those with a lower value(<6 miu/l) are 
less likely to progress. 
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  THYROID FUNCTION TEST  
The principal value of these tests is in assessing the thyroid status 
when the clinical picture is equivocal. However, even if clinical diagnosis 
appears quite certain it is valuable to have confirmatory evidence. Several 
parameters should be obtained because no single test is conclusive. These tests 
are used in the investigations of the patient with doubtful toxicity, in the 
diagnosis of hypothyroidism .  
 
THYROID FUNCTION TEST CAN BE CLASSIFIED AS 
FOLLOWS  
  1)Blood test 
  2)Non Blood test  
     TSH, T4, T3 and Free T4 are the blood tests  which are widely 
used and  readily available. To evaluate thyroid function following test are 
done: 
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        TSH Tests 
   Measuring TSH level in blood sample is the best initial test for 
thyroid function. A direct problem in thyroid (primary hypothyroidism) is 
suggested by a raised TSH level. The opposite happens in hyperthyroidism 
where there is low levels of TSH indicating an overactive thyroid producing 
excess of thyroid hormones. Occasionally pituitary gland abnormality will result 
in low levels of TSH which will then result in thyroid dysfunction (secondary 
hypothyroidism). A normal TSH level  indicates  that the thyroid is normally 
functioning in most healthy individuals. 
      T4 Tests 
Two forms of T4 circulates in the blood: 1)Protein bound T4 prevents 
T4 from entering metabolically active tissues requiring thyroid hormones and 2) 
free T4, which exerts its action after entering the various. Thyroid function 
cannot be determined without taking the free T4 fraction, and tests   which 
measure this are called the Free T4 index(FT4I or FTI) and the Free T4 (FT4). 
An elevated levels of free T4 or free T4 index will be seen in individuals with 
hyperthyroidism, whereas low levels of free T4 or free T4 index will be seen in 
individuals with hypothyroidism. Thyroid gland fuction can be accurately 
determined by combining the TSH levels and free T4 or free T4 index. Primary 
hypothyroidism because of disease in thyroid gland is indicated by elevated 
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TSH levels and low free T4 levels or low free T4 index. Hypothyroidism 
secondary to disease in pituitary  gland is indicated by low TSH and low free T4 
levels or low free T4 index. Individuals with hyperthyroidism will have 
lowTSH levels and an elevated free T4 levels or low free T4 index. 
           T3 Tests 
For diagnosis of hyperthyroidism or to assess the severity of 
hyperthyroidism blood levels  of T3 are very useful. An elevated T3 levels will 
be seen in hyperthyroid individuals. Only an elevated T3 levels with a normal 
free T4 or free T4 index will be seen in some individuals with low TSH levels. 
T3 becomes abnormal last in individuals with hypothyroidism,so rarely used for 
diagnosis of hypothyroidism. Even patients with severe hypothyroidism with a 
raised TSH levels and low free T4 levels or low free T4 index can have a 
normal T3 test.  During pregnancy or females on birth control pills, raised levels 
of T4 or T3 can be seen due to increased protein binding because of estrogen 
hormone. In these situations,TSH levels and free T4 or free T4 index should be 
done for thyroid function. 
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Thyroid Antibody Tests 
Thyroid dusfunction caused by two antibodies that are directed 
against thyroid cell proteins: thyroid peroxidase and thyroglobulin. 
Measurement of  thyroid antibody levels can  help to diagnose thyroid 
problems. For example, Hashimoto‘s thyroididtis can be diagnosed by positive 
anti-thyroid peroxidase and/or anti-thyroglobulin antibody levels  in a patient 
with hypothyroidism. Autoimmune thyroid disease can be diagnosed if the  
antibodies are positive in a hyperthyroid patient. 
     Thyroglobulin 
Normal thyroid gland and also thyroid cancer cells produce a protein 
called Thyroglobulin (Tg). In patients with intact thyroid gland,it does not  
measure  thyroid function and it does not diagnose thyroid cancer. It is used to 
monitor patients after treatment of thyroid cancer who have undergone 
thyroidectomy. 
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      NON-BLOOD TESTS 
      Radioactive iodine uptake  
The thyroid gland must extract a large amount of iodine out of the 
blood stream so that the gland can incorporate appropriate amount of iodine in 
T4. A very active mechanism is present in the thyroid gland for carrying out this 
function. By asking patients to swallow a small amount of radioactive iodine 
this active mechanism can be assessed to measure thyroid function. The 
radioactivity helps to track where the iodine molecules go. One can assess 
whether the thyroid gland is functioning normally or not, by measuring the 
amount of radioactivity taken up by the thyroid gland (radioactive iodine 
uptake, RAIU). When the thyroid gland is overactive(hyperthyroidism), a very 
high RAIU will be  seen in individuals while a low RAIU will be seen when the 
thyroid gland is underactive (hypothyroidism). 
                             In addition to  the above tests, a thyroid scan may 
be done, which shows a picture of the thyroid gland. 
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        PREVALENCE OF THYROID DISORDERS IN 
DIABETES MELLITUS 
It is known that Diabetes and thyroid diseases influence each other 
mutually. Several reports suggest a higher than normal prevalence of thyroid 
dysfunction among diabetics. This was found to be more common in patients 
suffering from  Type 1 Diabetes than among Type 2 Diabetics. 
This is understandable as both conditions have auto immunity as a 
common underlying mechanism. In addition, positive TPO anti bodies have 
been reported in as many as 38% 0f Diabetic patients and this has been shown 
to predict the development of sub clinical hypothyroidism. 
Even in Type 2 Diabetes the association is significant. Previous 
studies show a prevalence varying from 6.6% to 13.4%. 
The possible mechanisms by which Diabetes influences Thyroid 
status are: 
1. In diabetics, the nocturnal TSH peak is blunted or abolished and 
the TSH response to TRH is impaired.
 
 
2. Reduced T3 levels have been noted in patients with uncontrolled 
Diabetes. This could be explained due to reduced peripheral conversion of T4 
toT3. 
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EFFECTS OF THYROID DYSFUNCTION ON DIABETES 
The different mechanisms by which thyroid dysfunction affect the 
Diabetes status are: 
1. Thyroid dysfunction, both hypothyroididsm and hyperthyroidism 
are associated with increased insulin resistance.  
2. In hypothyroidism the renal clearance of insulin is decreased 
resulting in reduced insulin requirements. 
3. The loss of appetite seen in hypothyroidism contributes to 
decreased insulin requirements.  
4. Hypothyroid patients especially Type 1 Diabetics have a reduced 
rate of gluconeogenesis hence these patient have an increased incidence of 
hypoglycemia. 
5.  Even subclinical hypothyroidism has a negative impact on lipid 
metabolism and it is an independent risk factor for myocardial infarction and 
retinopathy  
6. Another possible mechanism linking SCH to vascular diseases is 
the finding that thyroid hormones inhibit collagen induced platelet aggregation 
and directly relax smooth muscles.  
7. Further hypothyroidism is accompanied by a hypercoagulable state 
and increased blood viscosity.  
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Thus presence of associated thyroid dysfunction has significant 
implications when it comes to glycemic control, insulin resistance, glycemic 
control and complications of Diabetes. 
Patients with associated hypothyroidism have been noted to have a 
higher incidence of microvascular complications especially nephropathy and 
retinopathy. These patients have a higher risk of having much more severe 
retinopathy too. The effects of hypothyroidism on platelet function and its 
rheological effect are said to play an important role in this regard. 
A higher prevalence of thyroid dysfunction (especially SCH) has been 
noted in the south and south east-asians having Type 2 DM. Screening with 
TSH measurement is not expensive. However, the cost-effectiveness of 
screening diabetic patients for thyroid dysfunction is likely to depend on a 
number of factors like local prevalence, ethnicity, as well as on the question of 
whether sub-clinical hypo- and  hyperthyroidism should be treated, which  itself 
is not fully resolved. 
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EFFECTS  OF THYROID HORMONES ON PATHOGENESIS 
OF DIABETIC RETINOPATHY 
 Numerous factors have been implicated in the pathogenesis of retinal 
new vessels, including erythropoietin, growth hormone, basic fibroblast growth 
factor (bFGF), insulin-like growth factor 1 (IGF-1), and VEGF.  
Other class of molecules involved in pathogenesis of retinal new 
vessels other than growth factors include integrins which act as specific 
extracellular matrix proteins. Integrin ανβ3 is usually not expressed on 
microvessels but is increased in response to angiogenic stimulation. New 
vessels in ocular tissue from patients with diabetic retinopathy especially 
proliferative diabetic retinopthy have shown selective upregulation of integrin  
ανβ3 and ανβ5. 
Integrin ανβ3 is an important regulator of angiogenesis. Various 
studies have shown that pharmacologic inhibition of this integrin blocks new 
vessels in multiple animal models. 
Integrin ανβ3 has pro – angiogenic effects on various growth factors 
including vascular endothelial growth factor (VEGF). On stimulation with 
VEGF,  it  interats  with vascular endothelial growth factor receptor 2 
(VEGFR2) and  forms a complex with VEGFR2. Inhibition of integrin ανβ3 
results in decreased VEGFR2 autophosphorylation and signalling.  
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The molecular mechanism for pro - angiogenic of  thyroid hormones 
is genomic and nongenomic. It is initiated non - genomically by integrin. 
Integrin ανβ3 has cell surface receptor site for thyroid hormone for L – 
thyroxine (T4) that mediates  pro - angiogenic action of thyroid hormones.  
Kinase transduction of the thyroid hormone signal and finally transcription of 
many angiogenic genes result. 
In a study by Takeshi Yoshida et al, inhibition of retinal 
neovascularisation by the integrin ανβ3 antagonist tetraiodothyroacetic acid 
(tetrac) has been documented. 
Integrin ανβ3 is a promising therapeutic target for retinal 
neovascularization and for modulating the pro – angiogenic activity of growth 
factors. 
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AIMS AND OBJECTIVES 
 
 
1. To assess the prevalence of Thyroid dysfunction among Type 2 
DM patients. 
2. To assess the prevalence of retinopathy among Type 2 Diabetes 
patients.  
3. To assess whether thyroid dysfunction is associated with increased 
risk of retinopathy in type 2 diabetes patients. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
This is a case control study. 
This study was conducted among 100 Type 2 DM patients attending 
the OP as well as in the wards at Govt.Rajaji.Hospital Madurai. 
Subjects were evaluated for entry into the study if they are 12 years of 
age or  older.  Subjects believed to fulfill all eligibility criteria, and none of the 
exclusion criteria, were invited to participate in the study. 
 
STUDY PERIOD: 
9 Months ( April 2014 to August 2014 ) 
SELECTION OF STUDY SUBJECTS: 
A total of 100 patients attending the O.P units and in the wards of the 
department of Ophthalmology, Government Rajaji Hospital Madurai who 
satisfy the inclusion criteria  
 
INCLUSION CRITERIA: 
1. Patients diagnosed with Type 2 Diabetes on treatment. 
2. Duration>5 years of diabetes mellitus. 
3. Age>12 yrs 
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EXCLUSION CRITERIA: 
1. Patients with known history of thyroid disorder. 
2. Patients on drugs known to affect thyroid function like Lithium ,  
Amiodarone, oral contraceptive pills, e.t.c. 
3. Pregnant Patients. 
4. Patients in whom fundus cannot be examined. 
5. Patients not consenting for the study. 
6. Systolic BP>140 and Diastolic BP>90. 
7. Glaucoma patients. 
8. Nephropathy patients. 
 
DATA AND SAMPLE COLLECTION: 
Data and Blood samples will be collected from established cases of 
type two diabetes patients on treatment from which serum shall be extracted for 
Thyroid  Profile. 
 
ASSESSMENT OF THYROID PROFILE: 
The Thyroid Profile will be estimated from the serum samples of the 
selected patients by Elisa technique at the endocrinology department. T3 T4 and 
TSH levels will be estimated. 
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 Normal thyroid profile: 
 
Test Abbreviation Typical Ranges 
  Serum thyroxine  T4 4.6-12ug/dl 
  SerumTriiodothyronine  T3 80-180 ng/dl 
  Seruthyroid stimulating  TSH 
 
0.5-6uIU/ml 
            hormone. 
 
The following guidelines for detection of thyroid dysfunction were 
considered – 
 
- Normal – when T3, T4 and TSH were within the normal range.  
- Primary hypothyroidism – when TSH is more than 6 μIU/ml and 
T3, T4        is less than the normal value.  
- Primary hyperthyroidism --when TSH is less than 0.5 μIU/ml and 
T3, T4 is more than the normal values.  
- Subclinical hypothyroidism – when TSH is more than 6 μIU/ml 
and T3, T4 is within the normal range.  
- Subclinical hyperthyroidism – when TSH is less than 0.5 μIU/ml 
and T3, T4 are within the normal range.  
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       ASSESSMENT OF RETINOPATHY: 
All the study patients will be  assesssd by an ophthalmologist for a 
detailed ocular examination for detection and grading of retinopathy. The 
prevalence of hypothyroidism in patients with and without diabetic retinopathy 
will be analyzed. 
 
ETDRS 
 
has classified NPDR into mild, moderate, severe and very 
severe and PDR into early PDR and high-risk PDR. This is as follows: 
 
                A. Mild NPDR: Presence of at least one microaneurysm, definition 
not met for B, C, D, E, or F. 
 
 B. Moderate NPDR: Hemorrhages and/or microaneurysms, presence 
of soft exudates, venous beading, IRMA definitely present, definition not met 
for C, D, E, or F. 
 
 C. Severe NPDR: Hemorrhages and/or microaneurysms in all four 
quadrants, or venous beading in two or more quadrants, or IRMA > standard 
photo 8A in at least one quadrant, definition not met for D, E, or F. 
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 D. Very severe NPDR: Any two or more of the changes seen in 
severe NPDR,   definition not met for E, or F. 
 
 E. Early PDR: Presence of new vessels, definition not met for F. 
 
 F. High-risk PDR: Includes any of the following characteristics -    
neovascularization of disc (NVD) > 1/3
 rd
 to 1/4
 th
 disc diameter, NVD < 1/3
 rd
 to 
1/4
 th
 disc diameter with vitreous/pre-retinal hemorrhage, NVE with 
vitreous/pre-retinal hemorrhage. High-risk characteristics (HRC) were defined 
by DRS, as the patient, if not treated urgently, is at a high risk of severe visual 
loss                                         
 G.  Diabetic maculopathy: 3 types-focal Maculopathy- presence of 
micro  aneurysms, hemorrhage, macular edema and hard exudates arranged in 
circinate pattern. Diffuse maculopathy- presence of diffuse retinal edema and 
thickening. Ischemic maculopathy- marked visual loss with micro aneurysms, 
hemorrhage, mild or no macular edema 
 H. Advanced eye disease: persistent vitreous hemorrhage, Tractional 
retinal detachment, and Neovascular glaucoma. 
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OBSERVATIONS AND STATISTICAL ANALYSIS 
DESCRIPTIVE ANALYSIS 
Age Distribution  
The age of the patients studied varied from 37 years to 78. 
 
 
 
 
 
 
 
 
 
                                                     AGE 
 
 
 
 
 
Age group Frequency Percent Valid Percent 
Cumulative 
Percent 
 35-45 12 12.0 12.0 12.0 
45-55 37 37.0 37.0 49.0 
55-65 36 36.0 36.0 85.0 
65-75 13 13.0 13.0 98.0 
75-85 2 2.0 2.0 100.0 
Total 100 100.0 100.0  
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Figure 1 Bar diagram showing age distribution of study population 
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       SEX DISTRIBUTION 
Among the 100 patients 50 were males and 50 females. 
SEX 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 Females 50 50.0 50.0 50.0 
Males 50 50.0 50.0 100.0 
Total 100 100.0 100.0  
 
 
 
Figure 2 Pie chart showing sex distribution of study population 
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    DURATION OF DIABETES 
The study group had an duration of Diabetes of  minimum 5 years and 
a maximum of 20 years. 
 
 
 
 
 
 
 
 
 
 
 
                  Figure 3 Bar Diagram showing duration of illness in study population 
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  SEX DISTRIBUTION OF THYROID DYSFUNCTON AMONG     
THE  PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEX 
THYROID DYSFUNCTON 
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NUMBER 
 
PERCENTAGE 
 
NUMBER 
 
PERCENTAGE 
 
MALES 
 
7 
 
14% 
 
43 
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FEMALES 
 
16 
 
32% 
 
34 
 
68% 
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Figure 4 Bar Diagram depicting sex distribution of thyroid dysfunction 
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       SEX DISRIBUTION OF RETINOPATHY 
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Figure 4 Bar Diagram depicting sex distribution of retinopathy 
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 RELATIONSHIP OF RETINOPATHY & DURATION OF ILLNESS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
 
  Figure 5 Bar diagram depicting relationship between retinopathy and duration of  Diabetes. 
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      PREVALENCE OF THYROID DYSFUNCTION 
Out of the 100 patients with diabetes 23 had thyroid dysfunction, the 
most common being sub-clinical hypothyroidism which was seen in 21 
patients.2 patients had frank hypothyroidism. 
 
 
                             
           Figure 6 Pie chart depicting distributon of thyroid dysfuncton in study populaton 
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      PREVALANCE OF RETINOPATHY 
Among the 100 patients studied 50 had diabetic retinopathy. Of which 
46  had NPDR while 4  had PDR. 
 
Figure 8 Pie chart depicting distribution of retinopathy in the study population 
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              ASSOCIATION BETWEEN RETINOPATHY AND 
THYROID DYSFUNCTION 
Among the 50 patients with retinopathy 18 had some form of thyroid 
dysfunction while among the remaining 50 patients without retinopathy  it was 
seen in 5. 
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           Figure 9 Bar diagram depicting association between retinopathy and thyroid dysfunction 
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     STASTICAL ANALYSIS 
ODD’S BASED ESTIMATE AND CONFIDENCE LIMITS 
 
 
Odds ratio (OR) is a measure of the association between a risk factor ( 
exposure) and a disease( outcome) applied in case control studies. 
 
An OR>1 means exposure is associated with higher odds of outcome 
 
 
Confidence limits or intervals (CI) are used to measure the precision 
of the Odds Ratio .A large CI indicates less precision while a small CI indicates 
high precision for the OR.  
 
Thus in the current study  the Odds Ratio came out to be 5.06 with an 
upper 95% confidence limit of 15.051 and a lower confidence limit of 1.703. 
Which means the odds of a Diabetic patient with thyroid dysfunction 
( sub clinical and overt hypothyroidism) developing retinopathy is 5.06 times 
that of a Diabetic patient without  thyroid dysfunction developing the same. 
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      TEST OF SIGNIFICANCE 
In order to test the significance of above described association 
between thyroid dysfunction, considered the risk factor, and retinopathy, the 
disease,  Chi Square statistic was applied.  
The categorical data was displayed in a 2x2 contingency table.  
 
 
 
       
 
     THYROID 
DYSFUNCTION 
 
DISEASE 
 
 
TOTAL RETINOPATHY 
PRESENT 
RETINOPATHY 
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E 
X 
P 
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U 
R 
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   PRESENT 
 
18 
 
05 
 
23 
             
           ABSENT 
 
32 
 
45 
 
77 
 
TOTAL 
 
50 
 
50 
 
100 
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       An easier formula for a 2x2 table is: 
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We get a chi square value of 
100{(18x45)-(32x05)}
2 
   =   9.543 
                      50x50x23x77 
Comparing with the log tables this value corresponds to a P-value of   
< .005 which means the association between the risk factor and disease is not 
just by chance and is significant. 
 
 
       THYROID 
DYSFUNCT
-ION 
RETINOPATHY 
PRESENT 
RETINOPATHY 
ABSENT 
TOTAL 
  
 PRESENT 
 
18 
 
05 
 
23 
       
ABSENT 
 
32 
 
45 
 
77 
 
TOTAL 
 
50 
 
50 
 
100 
104 
 
DISCUSSION 
IN OUR STUDY 
ODDS RATIO 95% CONFIDENCE         
INTERVAL 
     P-VALUE 
         5.06              1.703 – 15.051       <0.005 
 
According to this study the prevalence of thyroid dysfunction among 
the 100 Type 2 Diabetes Mellitus patients studied was 23% with the most 
common problem being sub-clinical hypothyroidism(SCH) at 21% among the 
study population followed by overt hypothyroidism at 2%. As expected the 
prevalence of thyroid dysfunction among females (32%) was much more than 
among males (14%). 
These results are in tune with those obtained from previous similar 
studies. In  an Indian study  conducted at D Y Patil Medical College Mumbai by 
Vinu Vij et al. an increased prevalence of Hypothyroidism was noted among 
Type 2 DM patients and it was found to adverse effect on retinopathy. 
In another study published in ―Advances in Bio Research Volume 2, 
Issue 2, December 2011‖ authored by  Gurjeet Singh et al. the thyroid profile in 
80  type 2 diabetic patients was, compared with 80 non-diabetic patients. The 
level of T3, T4, FT3 and FT4were significantly lower while the level of TSH was 
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significantly higher in type 2 diabetics as compared to non-diabetics.  From the 
80 diabetic subjects studied, 30% showed abnormal thyroid hormone levels 
(23.75% had hypothyroidism including SCH  and 6.25% had hyperthyroidism). 
Significantly higher levels of FPG, HbA1c, serum cholesterol, serum 
triglyceride, LDLVLDL, blood urea, creatinine, SGOT, SGPT and significantly 
lower level of HDL was observed in diabetics as compared to non-diabetics 
subjects 
In a study by Diez jj et al
8
 (Exp clin Endocrinol Diabetes 2011 April)  
318 patients with Diabetes mellitus were evaluated for thyroid dysfunction.The 
number of patients with thyroid dysfunction and their respective prevalence 
were: overt hyperthyroidism, 11 (3.5%);  subclinical hyperthyroidism, 10 
(3.1%);  overt hypothyroidism, 48 (15.1%), and  subclinical hypothyroidism, 34 
patients (10.7%).  The screening program detected the following cases of newly 
diagnosed thyroid dysfunction: subclinical hyperthyroidism, 5 (1.6%); overt 
hypothyroidism, 6 (1.9%), and subclinical hypothyroidism, 20 patients (6.3%).  
Comparing to the above study the prevalence of  SCH and 
hypothyroidism were similar.  
Coming to the association between thyroid dysfunction and 
retinopathy, our study showed a significant association between SCH and overt 
hypothyroidism and retinopathy in the study population, with a odds ratio of 
5.06 and a P-value of <0.005. 
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JIN-KUI YANG et al
 
studied
 
1170 Type 2 DM patients and they too 
found this association to be significant. They also concluded that 
hypothyroidism is a risk factor for more severe sight threatening proliferative 
retinopathy. 
In a Korean study by Bo-Yeon Kim et al 637 patients with Type 2 
DM were screened for retinopathy between 2001 and 2007.The prevalence of 
severe diabetic retinopathy was significantly higher in the hypothyroid group 
compared to the euthyroid group.( 32.8 vs 19.6 p-value = .036) 
In our study the number of patients with PDR was only 4 and this 
number was too less to study an association between thyroid dysfunction and 
severity of retinopathy. 
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             LIMITATIONS OF THIS STUDY 
-The study population was small. 
             -The relationship between thyroid dysfunction and severity of 
retinopathy could not be studied due to the small size of the study population. 
               -Only hypertension and nephropathy were ruled out among the study 
population. Factors like dyslipidemia which are associated with both thyroid 
dysfunction and retinopathy were not ruled out.  
-Thyroid function tests did not include free T4 and free T3. 
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        CONCLUSION 
- The prevalence of retinopathy in Type 2 Diabetes patients is 50%. 
- The prevalence of thyroid dysfunction among Type 2 Diabetes 
patients is 23%. 
- Sub clinical hypothyroidism is the most common thyroid 
abnormality among Type 2 diabetics at 21%. 
- Prevalence of hypothyroidism in Type 2 DM is 2% and that of 
hyperthyroidism is 0%. 
- Sub-clinical and overt hypo thyroidism are associated with an 
increased risk of retinopathy.  
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     RECCOMENDATIONS 
-  One should have a high index of suspicion regarding the presence 
of thyroid dysfunction among Type 2 Diabetics. 
-  Routine screening for Thyroid dysfunction is recommended in all 
patients with retinopathy. 
- Further trials studying the impact of treatment of thyroid 
dysfunction on the complications of Diabetes need to be carried out. 
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                                                          PROFORMA 
 
NAME:                                                           IP/OP NO: 
 
AGE:                                                              DURATION OF DM:      
 
SEX:                                                              DATE OF SAMPLE COLLECTION: 
 
OCULAR EXAMINATION: 
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SEVERE NPDR  
VERY SEVERE NPDR  
EARLY PDR  
HIGH RISK PDR  
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MASTER CHART 
 
SR NO  NAME IO/OP NO  AGE SEX VISION IOP  DURATIO
N OF DM 
RE LE RE LE 
1 SARASWA
TI 
635748 60 FEMALE 6/12,6/12 18,18 7 YEARS 
2 MALLIGA 659918 60 FEMALE 6/9,6/12 19,19 6 YEARS 
3 NOORJAH
AN 
647343 56 FEMALE 6/9,6/9 18,18 8 YEARS 
4 MUNIYAM
MAL 
647254 40 FEMALE 6/18,6/24 17,17 5 YEARS 
5 SHANTI 647251 43 FEMALE 6/6,6/6 15,16 5 YEARS 
6 MUTHUR
ANI 
646480 47 FEMALE 6/9,6/12 20,20 8 YEARS 
7 MUTHULA
KSHMI 
647262 50 FEMALE 6/24,6/60 19,20 7 YEARS 
8 VALLIAM
MAL 
648160 52 FEMALE 3/60,4/60 18,18 10 YEARS 
9 SERINABE
GAM 
650161 42 FEMALE 6/6,6/6 17,18 5 YEARS 
10 BACKIYAM 659745 40 FEMALE 6/12,6/18 18,18 6 YEARS 
11 JAYALAKS
HMI 
650228 56 FEMALE 6/24,6/18 20,20 9 YEARS 
12 TAMILARA
SI 
650200 50 FEMALE 6/12,6/12 17,17 5 YEARS 
13 VEERAYEE 650242 53 FEMALE 6/36,6/24 18,18 8 YEARS 
14 MEENACH
I 
630241 70 FEMALE 6/24,6/60 19,20 13 YEARS 
15 PANDIYA
MMAL 
650571 41 FEMALE 6/18,6/9 17,17 7 YEARS 
16 VASANTHI 650603 56 FEMALE 6/12,6/9 19,18 9 YEARS 
17 AARAYEE 650546 44 FEMALE 6/9,6/12 15,15 5 YEARS 
18 PARVATH
Y 
650616 58 FEMALE 6/12,6/12 18,18 10 YEARS 
19 MAHALAK
SHMI 
650418 61 FEMALE 6/18,6/24 20,20 11 YEARS 
20 SUBBU 648904 40 FEMALE 6/12,6/12 18,18 5 YEARS 
21 RAKKU 614812 80 FEMALE 6/18,6/18 20,20 15 YEARS 
22 OYYAMM
AL 
650839 58 FEMALE 6/6,6/6 16,15 5 YEARS 
23 PUSHPAM 650167 50 FEMALE 6/60,6/36 19,20 10 YEARS 
24 SELVI 650294 40 FEMALE 6/18,6/12 15,17 6 YEARS 
25 CHINNAP
ONNU 
650302 45 FEMALE 6/6,6/6 18,16 9 YEARS 
26 AMIRTHA
M 
84725 55 FEMALE 6/24,6/9 16,17 6 YEARS 
27 PICHAYA
MMAL 
81706 40 FEMALE 6/9,6/9 17,19 7 YEARS 
28 VALARMA 650961 60 FEMALE 6/36,6/36 19,20 9 YEARS 
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THI 
29 ALAGAM
MAL 
650990 45 FEMALE 6/12,6/18 15,16 8 YEARS 
30 PANDIYA
MMAL 
651133 54 FEMALE 6/18,6/12 19,19 7 YEARS 
31 VICTORIA
MARY 
650960 45 FEMALE 6/12,6/12 18,18 6 YEARS 
32 LEELA 650989 70 FEMALE 6/60,6/36 19,18 13 YEARS 
33 VETRISELV
I 
651180 57 FEMALE 6/12,6/18 16,16 8 YEARS 
34 JOTHIMA
NI 
651184 47 FEMALE 6/12,6/12 17,18 9 YEARS 
35 KAMALA 651293 67 FEMALE 6/18,6/18 19,19 15 YEARS 
36 ELAMMAL 651272 52 FEMALE 6/60,2/60 16,17 7 YEARS 
37 KAALIAM
MAL 
651667 57 FEMALE 6/12,6/12 18,18 9 YEARS 
38 GOMATHI 651731 57 FEMALE 6/12,6/24 14,16 6 YEARS 
39 BALAMM
AL 
651940 63 FEMALE 6/12,6/18 19,20 15 YEARS 
40 KALAISELV
I 
651907 57 FEMALE 6/18,6/18 17,18 9 YEARS 
41 RAKKAM
MAL 
651885 48 FEMALE 6/12,6/9 20,20 5 YEARS 
42 LEELA 652024 52 FEMALE 6/18,6/12 19,19 8 YEARS 
43 VALLI 652031 55 FEMALE 6/36,6/9 18,18 10 YEARS 
44 MANJULA 652052 50 FEMALE 6/9,6/12 18,17 6 YEARS 
45 EMILI 652658 65 FEMALE 6/60,6/60 16,16 13 YEARS 
46 ALAGU 653843 58 FEMALE 6/24,6/9 17,17 9 YEARS 
47 VANITHA 653959 47 FEMALE 6/6,6/9 13,13 5 YEARS 
48 ANDICHI 653912 50 FEMALE 6/9,6/9 15,17 10 YEARS 
49 JAYA 655965 58 FEMALE 6/18,6/18 19,19 9 YEARS 
50 VASANTH
A 
636691 61 FEMALE 6/60,6/12 14,13 7 YEARS 
51 ARUMUG
AN 
654175 55 MALE 6/12,6/18 16,15 9 YEARS 
52 PALPANDI 654133 70 MALE 6/18,6/24 17,18 12 YEARS 
53 ANBARAS
U 
652694 48 MALE 6/9,6/6 12,10 5 YEARS 
54 MURGAIY
AH 
652693 58 MALE 6/9,6/9 13,12 7 YEARS 
55 KANNAN 653848 63 MALE 6/12,6/18 13,13 7 YEARS 
56 VIJAYKUM
AR 
611275 40 MALE 6/9,6/9 17,17 5 YEARS 
57 RAJA 653089 63 MALE 6/6,6/9 18,18 15 YEARS 
58 SHANTAN
U 
653092 50 MALE 6/12,6/12 17,17 12 YEARS 
59 JAGANNA
THAN 
653115 47 MALE 6/9,6/24 17,17 5 YEARS 
60 NAGARAJ
AN 
646483 48 MALE 6/12,6/12 15,15 8 YEARS 
61 PALRAJ 647271 62 MALE 6/9,6/12 19,19 15 YEARS 
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62 MOOKAN 647341 53 MALE 6/9,6/24 16,17 9 YEARS 
63 MUTHUSA
MY 
647461 67 MALE 6/12,6/18 18,18 6 YEARS 
64 MUTHU 647421 65 MALE 6/6,6/12 17,17 10 YEARS 
65 BASKARA
N 
647241 78 MALE 6/12,6/12 17,17 20 YEARS 
66 CHINNAD
URAI 
690406 58 MALE 6/60,6/36 19,20 8 YEARS 
67 MANOHA
RAN 
648130 45 MALE 6/6,6/9 14,14 7 YEARS 
68 KARUPPAS
AMY 
648160 59 MALE 5/60,6/60 20,20 12 YEARS 
69 SHEIKHDA
WOOD 
648187 65 MALE 6/36,6/9 18,17 10 YEARS 
70 RAMALAY
AI 
648193 54 MALE 6/12,6/9 16,16 7 YEARS 
71 RAMAIYA 648621 59 MALE 6/24,6/18 17,18 9 YEARS 
72 SHAKEELA
HMED 
648519 47 MALE 6/12,6/9 15,15 5 YEARS 
73 MURUGES
AN 
648123 50 MALE 6/6,6/9 18,18 7 YEARS 
74 SAHULAH
MED 
649372 37 MALE 6/6,6/6 13,13 5 YEARS 
75 HARIKRIS
HNAN 
649351 66 MALE 3/60,1/60 20,20 16 YEARS 
76 DEVENDR
AN 
649338 56 MALE 6/36,6/9 18,17 8 YEARS 
77 MURUGA
N 
678864 60 MALE 6/24,6/24 17,17 9 YEARS 
78 VEERASA
MY 
649402 58 MALE 6/9,6/9 16,16 12 YEARS 
79 MAHALIN
GAM 
649342 54 MALE 6/36,6/60 18,18 9 YEARS 
80 SELVARAJ
AN 
649642 46 MALE 6/9,6/12 15,15 7 YEARS 
81 VAHAB 649671 50 MALE 6/9,6/12 16,16 14 YEARS 
82 NARSEEM
A 
650159 45 MALE 6/9,6/9 13,13 7 YEARS 
83 GANESAN 650227 65 MALE 6/60,6/12 15,15 10 YEARS 
84 RAJASEKA
R 
650213 58 MALE 6/18,6/12 17,18 11 YEARS 
85 ABDULKA
REEM 
650249 66 MALE 6/12,6/9 19,20 8 YEARS 
86 RAJA 650644 48 MALE 6/12,6/9 14,14 5 YEARS 
87 SUBAHAN 650707 58 MALE 6/24,6/18 15,16 9 YEARS 
88 PARAMAS
IVAM 
650852 42 MALE 6/12,6/12 17,17 6 YEARS 
89 MURUGA
N 
650895 52 MALE 6/9,6/60 18,18 5 YEARS 
90 GOVINDH
RAJ 
650273 51 MALE 6/12,6/18 17,18 7 YEARS 
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91 KARTHIK 650305 45 MALE 6/12,6/9 19,17 5 YEARS 
92 MUTHU 650335 49 MALE 6/6,6/6 13,13 5 YEARS 
93 DEVARAJ 650297 54 MALE 4/60,6/60 18,18 9 YEARS 
94 JAYARAM 650367 51 MALE 6/12,6/12 17,17 7 YEARS 
95 SELVAM 650311 60 MALE 6/12,6/18 15,15 8 YEARS 
96 RUSHTAM 650299 57 MALE 6/60,6/36 19,19 5 YEARS 
97 PERIYAKA
RUPAN 
650310 65 MALE 6/12,6/12 14,14 15 YEARS 
98 MAHENDR
A 
650300 55 MALE 6/9,6/9 17,17 8 YEARS 
99 CHINNAR
AMAN 
650992 60 MALE 6/12,6/12 17,17 10 YEARS 
100 PITCHAI 651141 69 MALE 6/9,6/9 17,17 20 YEARS 
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